pegylated liposomal doxorubicin + veliparib

Pegylated liposomal doxorubicin + veliparib is an investigational combination therapy consisting of two agents: - **Pegylated liposomal doxorubicin (PLD)** is a formulation of the anthracycline chemotherapeutic agent doxorubicin encapsulated in a pegylated liposome, which enhances drug delivery to tumors and reduces cardiotoxicity. It acts primarily as a DNA intercalator and topoisomerase II inhibitor, leading to DNA damage and apoptosis in cancer cells. - **Veliparib** is an orally available small molecule inhibitor of poly(ADP-ribose) polymerase (PARP), particularly PARP1 and PARP2. By inhibiting these enzymes involved in DNA repair, veliparib potentiates the cytotoxic effects of DNA-damaging agents like PLD. This combination has been studied primarily for recurrent ovarian cancer, triple-negative breast cancer, fallopian tube cancer, and primary peritoneal cancer. The rationale for combining these drugs is that PARP inhibition by veliparib impairs tumor cell repair mechanisms following DNA damage induced by PLD, potentially increasing antitumor efficacy[1][3].

Other names

PLD + veliparibpegylated liposomal doxorubicin hydrochloride + veliparib